Can CSL shares bounce back? 3 experts share their views after brutal 36% sell-off

Tough year, but what comes next?

Key points
  • Healthcare giant CSL has had a difficult year as operational challenges began to emerge.
  • The company's share price has tumbled significantly since earnings season in August.
  • Three fund managers have now shared their views on the group's prospects.

Investors in CSL Ltd (ASX: CSL) have endured a tough year so far in 2025.

In August, shares in the healthcare titan tumbled by more than 21% after the company released its FY25 results.

In particular, an underperformance in its core plasma therapies business known as Berhing appeared to spook investors.

And another crunching blow followed this week.

On Tuesday, CSL shares dipped by 15% after it downgraded its earnings and revenue forecasts, whilst also halting plans to spin off its vaccines division.

Overall, shares in the company have now fallen by 36% since the start of the year to $179.56 per share at Thursday's close.

This compares with a solid 10% rise for the All Ordinaries Index (ASX: XAO) across the same period.

But where do CSL shares go from here?

Below we present the views of three portfolio managers from renowned Aussie investment firms, as reported in the Financial Review.

young female doctor with digital tablet looking confused.

Image source: Getty Images

DNR Capital sees opportunity following sell down

Chief investment officer at DNR Capital, Jamie Nicol, believes that this week's sell-off was "disproportionate".

He also appeared to see the recent dip in CSL shares as a buying opportunity.

Nicol noted that the selldown was mainly related to CSL's flu business, which he considers to be a fairly small proportion of the company's overall value.

He commented:

 There's been a big overreaction for something that's a small part of the business.

Adding that:

These are the sorts of opportunities you look for in markets.

Reportedly, CSL is one of DNR Capital's largest holdings.

Australian Ethical points to favourable valuation

Head of Australian equities at Australian Ethical Investment Ltd (ASX: AEF), Nathan Parkin, believes the fundamentals of the business remain sound, whilst recognising the market's reaction.

He commented:

It's been the second downgrade in a short period, but it doesn't really concern us in terms of the strength of Behring, the main business, which remains solid.

Meanwhile, this week's selldown appears to have created a valuation that Australian Ethical finds more favourable.

Parkin added:

Australian Ethical didn't hold CSL for more than a decade because they thought it was too expensive. Now we're seeing the flip side, the valuation looks appealing, and we think it's a good opportunity.

TenCap throws caution to the wind

However, portfolio manager at TenCap, Jun Bei Liu, appeared to take a more cautionary tone, stating:

For a growth company to start having those issues, it's really difficult to say to investors, 'trust me', when you have faltered so many times.

She added:

I wouldn't be surprised if management has to change as well when you disappoint that many times.

Motley Fool contributor Bart Bogacz has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Australian Ethical Investment and CSL. The Motley Fool Australia has recommended Australian Ethical Investment and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »